References
- Beahrs OH, Henson D, Hutter RVP, Kennedy BJ. American Joint Committee on Cancer handbook for staging cancer4th ed. JB Lippincott, Philadelphia, PA 1993
- Murphy WM, Dean PJ, Brasfield JA, Tatum L. Incidental carcinoma of the prostate. How much sampling is adequate?. Am J Surg Pathol 1986; 10: 170–4
- Newman AJ, Jr, Graham MA, Carlton CE, Jr, Lieman S. Incidental carcinoma of the prostate at the time of transurethral resection: importance of evaluating every chip. J Urol 1982; 128: 948–50
- Mettlin C, Jones GW, Murphy GP. Trends in prostate cancer care in the United States, 1974–1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin 1993; 43: 83–91
- Mostofi FK. Grading of prostatic carcinoma. Cancer Chemother Rep 1975; 59: 111–7
- Zigeuner RE, Lipsky K, Riedler I, Auprich M, Schips L, Salfellner M, et al. Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology 2003; 62: 451–5
- Miller BA, Ries LA, Hankey BF, Kossary CL, Harras A, Devesa SS, et al. SEER Cancer Statistics Review: 1973–1990. NIH Publication No. 93-2789. National Cancer Institute, Bethesda, MD 1993
- Barnes R, Hirst A, Rosenquist R. Early carcinoma of the prostate: comparison of stages A and B. J Urol 1976; 115: 404–5
- Amin MB, Grignon DJ, Humphrey PA, Srigley JR. Gleason grading of prostate cancer: a contemporary approach. Lippincott Williams & Wilkins, Philadelphia, PA 2004
- Rosai J, Ackerman LV. Surgical pathology9th ed. Mosby, EdinburghUK 2004
- Selman SH. “Latent” carcinoma of the prostate: a medical misnomer?. Urology 2000; 56: 708–11
- Fowler JE, Jr, Pandey P, Bigler SA, Yee DT, Kolski JM. Trends in diagnosis of stage T1a-b prostate cancer. J Urol 1997; 158: 1849–52
- Blackard CE, Mellinger GT, Gleason DF. Treatment of stage 1 carcinoma of the prostate: a preliminary report. J Urol 1971; 106: 729–33
- Monda JM, Barry MJ, Oesterling JE. Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia. J Urol 1994; 151: 1291–5
- Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–24
- Cantrell BB, DeKlerk DP, Eggleston JC, Boitnott JK, Walsh PC. Pathological factors that influence prognosis in stage A prostate cancer: the influence of extent versus grade. J Urol 1981; 125: 516–20
- Aus G, Becker C, Franzen S, Lilja H, Lodding P, Hugosson J. Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio. Eur Urol 2004; 45: 160–5
- Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H. Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL. Urology 2003; 61: 760–4
- Roobol MJ, Kranse R, de Koning HJ, Schroder FH. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology 2004; 63: 309–13
- Ito K, Ohi M, Yamamoto T, Miyamoto S, Kurokawa K, Fukabori Y, et al. The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4.1-10.0 ng/mL. Cancer 2002; 95: 2112–9
- Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71–4
- Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995; 45: 2–12
- Winkler MH, Kulinskaya E, Gillatt DA. Prediction of prostate cancer in extended-field biopsies of the prostate. BJU Int 2004; 93: 516–21
- Damiano R, Autorino R, Perdona S, De Sio M, Oliva A, Esposito C, et al. Are extended biopsies really necessary to improve prostate cancer detection?. Prostate Cancer Prostatic Dis 2003; 6: 250–5
- Ornstein DK, Rao GS, Smith DS, Andriole GL. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol 1997; 157: 880–3
- Egawa S, Greene DR, Flanagan WF, Wheeler TM, Scardino PT. Transrectal ultrasonography in stage A prostate cancer: detection of residual tumor after transurethral resection of prostate. J Urol 1991; 146: 366–71
- Greene DR, Egawa S, Neerhut G, Flanagan W, Wheeler TM, Scardino PT. The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. J Urol 1991; 145: 324–8